CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Accumulated Expenses of $74.9 million for Q1 2026, up 477.91% sequentially from $13.0 million in Q4 2025, and down 11.44% YoY from $84.6 million in Q1 2025.
CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Accumulated Expenses for 12 years, with the latest figure at $74.9 million in Q1 2026.
- Quarterly Accumulated Expenses fell 11.44% year-over-year to $74.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.9 million (down 11.44% YoY) and the FY2025 annual result came in at $13.0 million, down 68.43% from the prior year.
- Accumulated Expenses rose to $74.9 million in Q1 2026 per CRSP's latest filing, from $13.0 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $103.0 million in Q3 2022 and troughed at $8.6 million in Q2 2025.
- A 5-year average of $54.5 million and a median of $66.4 million in 2023 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses jumped 875.3% in 2023, then slumped 90.62% in 2025.
- Over 5 years, Accumulated Expenses stood at $19.2 million in 2022, then dropped by 9.84% to $17.3 million in 2023, then surged by 136.77% to $41.1 million in 2024, then tumbled by 68.43% to $13.0 million in 2025, then soared by 477.91% to $74.9 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $74.9 million, $13.0 million, and $84.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.28 Mn |
| Mar 31, 2026 | 74.93 Mn |
| Dec 31, 2025 | 12.97 Mn |
| Sep 30, 2025 | 84.18 Mn |
| Jun 30, 2025 | 8.62 Mn |
| Mar 31, 2025 | 84.62 Mn |
| Dec 31, 2024 | 41.07 Mn |
| Sep 30, 2024 | 47.20 Mn |
| Jun 30, 2024 | 91.88 Mn |
| Mar 31, 2024 | 76.43 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Sep 30, 2023 | 66.41 Mn |
| Jun 30, 2023 | 89.84 Mn |
| Mar 31, 2023 | 85.63 Mn |
| Dec 31, 2022 | 19.24 Mn |
| Sep 30, 2022 | 102.95 Mn |
| Jun 30, 2022 | 13.91 Mn |
| Mar 31, 2022 | 8.78 Mn |
| Dec 31, 2021 | 23.66 Mn |
| Sep 30, 2021 | 17.03 Mn |